RxSight (NASDAQ:RXST) versus Warby Parker (NYSE:WRBY) Critical Contrast

RxSight (NASDAQ:RXSTGet Rating) and Warby Parker (NYSE:WRBYGet Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares RxSight and Warby Parker’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
RxSight $22.59 million 15.08 -$48.69 million ($5.43) -2.28
Warby Parker $540.80 million 3.07 -$144.27 million N/A N/A

RxSight has higher earnings, but lower revenue than Warby Parker.

Profitability

This table compares RxSight and Warby Parker’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
RxSight -212.04% N/A -37.98%
Warby Parker N/A N/A N/A

Institutional and Insider Ownership

31.6% of RxSight shares are held by institutional investors. Comparatively, 98.6% of Warby Parker shares are held by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for RxSight and Warby Parker, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
RxSight 0 0 6 0 3.00
Warby Parker 0 4 5 0 2.56

RxSight presently has a consensus target price of $19.83, indicating a potential upside of 60.08%. Warby Parker has a consensus target price of $41.00, indicating a potential upside of 135.09%. Given Warby Parker’s higher possible upside, analysts clearly believe Warby Parker is more favorable than RxSight.

Summary

Warby Parker beats RxSight on 5 of the 9 factors compared between the two stocks.

RxSight Company Profile (Get Rating)

RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Warby Parker Company Profile (Get Rating)

Warby Parker Inc. provides eyewear products. It offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, and contact lenses, as well as accessories, including cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray. The company also offers eye exams and vision tests directly to consumers through its retail stores, website, and mobile apps. As of March 17, 2022, it had 160 retail stores in the United States and Canada. The company was formerly known as JAND, Inc. and changed its name to Warby Parker Inc. in June 2021. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York.

Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.